NIND

AcronymDefinition
NINDNational Industries Group Holding (stock symbol)
NINDNon-Inflammatory Neurological Disease
References in periodicals archive ?
Frequently, NINDS grantees are forced to balance their focus between advancing their research and technology objectives into healthcare products and the necessity of procuring funding and building partnerships to drive those advancements.
The ultimate goal of the DMFP is to support the NINDS and their BPN Contributors - drug companies and academic researchers C in the development and manufacture of dosage forms of small molecule drug candidates suitable for administration in preclinical and clinical studies of neurological disease/disorders.
Kovach, President and CEO of Lixte, said, "Studies with the research team at the Molecular Pathogenesis Unit, Surgical Neurology Branch, NINDS, identified a biomarker that appears to be preferentially targeted by novel anti-cancer drugs currently being evaluated by NINDS and Lixte as new treatments for human brain tumors.
What will the neuroscience research landscape look like in 15 years, and how can NINDS best contribute?
Here, visitors can learn more about what clinical trials really are; those who wish to participate in a clinical trial can choose from an extensive list of neurological conditions, from ADHD to Zellweger syndrome, to see what research is in progress or coming up at the NINDS and elsewhere across the country.
a program director in the NINDS Office of Translational Research and the lead contact for the Blueprint Neurotherapeutics Network.
President and CEO of Aquinnah said, "We are pleased to have received excellent reviews on our scientific program, leading NINDS to fund our proposal to develop innovative new therapies for the treatment of ALS.
An example of such a facility is the NINDS Human Genetics Resource Center (http://locus.
Under his guidance, many young scientists who come to the NINDS for advanced training in immunology have gone on to devote their professional lives to the MS problem.
4 million and was awarded under the NINDS Fast-Track Small Business Innovative Research Cooperative Program in Translational Research that supports the identification and preclinical testing of new therapeutics for neurological disorders.
Under a Cooperative Research and Development Agreement (CRADA) with the National Institute of Neurological Disorders and Stroke (NINDS), and upon receipt of an IND from the FDA, TSI will work with leading researchers at the NINDS / Intramural Stroke Program to test the safety of dual thrombolytic therapy using tissue plasminogen activator and an improved version of prourokinase (HisproUK) in patients suffering from acute ischemic stroke (AIS).
The ultimate goal of the DMFP is to support the NINDS and their BPN Contributors - drug companies and academic researchers in the development and manufacture of dosage forms of small molecule drug candidates suitable for administration in preclinical and clinical studies of neurological disease/disorders.